Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 21:21, 15 January 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Deslorelin

Clinical data
Pregnancy category	X (USA)
Routes of administration	implant / Inhalation
ATCvet code	QH01CA93 (WHO)
Pharmacokinetic data
Excretion	renal
Identifiers
IUPAC name (2S)-N--1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl) -1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
PubChem CID	7979044
CompTox Dashboard (EPA)	DTXSID2048323
ECHA InfoCard	100.165.050
Chemical and physical data
Formula	C64H83N17O12
Molar mass	1282.45 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES CCNC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC3=CC=N3)NC(=O)C4CCC(=O)N4)CC5=CC6=C5C=CC=C6)CC7=CC8=C7C=CC=C8
(verify)

Deslorelin acetate is an injectable gonadotropin releasing hormone super-agonist (GnRH agonist) also known as an LHRH agonist. It stops the production of sex hormones (testosterone and oestrogen).

Deslorelin Acetate is marketed by Peptech with the brand name Ovuplant. It is currently approved for use in veterinary medicine and is used to induce ovulation in mares as part of the artificial insemination process. It is also used to stabilize high-risk pregnancies, mainly of livestock. Unlike other GnRH agonists, which are mainly used to inhibit luteinizing hormone and follicle-stimulating hormone by their ultimate downregulation of the pituitary gland, Deslorelin is primarily used for the initial flare effect upon the pituitary, and its associated surge of LH secretion.

Pharmacokinetics

Deslorelin is a synthetic analogue of a naturally occurring luteinising-hormone releasing hormone (LHRH). Bioavailability is almost complete.

Clinical trials

Deslorelin was successfully trialed in the US and was approved for veterinary use under certain circumstances. In Europe, it was approved for use in equine assisted reproduction.

It is also being trialed in humans to study its efficacy in treatment of breast cancer in women, and in treating precocious puberty and congenital adrenal hyperplasia in male and female children.

As of early 2009, this drug is not approved for use in the US, other than within approved clinical trials.

References

1. Peptech official Ovuplant site
2. Deslorelin Acetate - European Agency for the Evaluation of Medicinal Products
3. Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease - National Cancer Institute
4. Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia - National Institutes of Health Clinical Center

This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• GnRH agonists
• Peptides
• Genito-urinary system drug stubs